VATE INNOVATE Corp.

MIXED Impact: 6/10 PRESS-RELEASE
Horizon weeks Filed Mar 26, 2026 Processed 2mo ago Wire GlobeNewswire
Press release: earnings
Latest settled — T+20d
VATE ▲ +161.87% at T+20d
NEUTRAL call ✓ call won +161.87% · α vs SPY +149.13% · entry $4.59 → $12.02
Next anchor: T+60d in 10d
Currently $16.72 · +264.27% from $4.59 entry
Entry anchored
Mar 26, 03:54 PM ET
via Databento tick
T+1d
+19.83%
call +19.83% · α +20.18%
$5.50
settled 3mo ago
T+5d
+63.18%
call +63.18% · α +59.32%
$7.49
settled 2mo ago
T+20d
+161.87%
call +161.87% · α +149.13%
$12.02
settled 7w ago
T+60d
call — · α —
in 10d

Price Chart

Loading chart...

Executive Summary

INNOVATE Corp. reported strong top-line growth for Q4 and full-year 2025, with revenue up 61.7% YoY in the quarter and 12.5% for the year, driven by its Infrastructure segment. Despite a net loss, losses narrowed significantly, and Adjusted EBITDA improved in the quarter. The company highlighted a $1.8 billion backlog, FDA approval for a key medical device, and a major international sales commitment in China, though Spectrum segment weakness and full-year Adjusted EBITDA decline temper overall optimism.

Key Financial Metrics

Revenue
$382.7M
+61.7% YoY
EPS
$-0.58

Actionable Insight

Traders should monitor the execution of the $1.8B Infrastructure backlog in 2026 and Spectrum segment recovery, as current earnings growth is concentrated in one segment and offset by declines elsewhere. The FDA approval and China deal in Life Sciences may provide long-term value, but near-term profitability remains pressured.

Key Facts

  • Q4 2025 revenue: $382.7M, up 61.7% YoY; full-year revenue: $1.246B, up 12.5% YoY
  • Q4 net loss: $7.8M vs. $16.9M loss in prior year; full-year net loss widened to $64.0M from $35.8M
  • Q4 Adjusted EBITDA: $24.5M, up 63.3% YoY; full-year Adjusted EBITDA declined 5.8% to $67.2M
  • Infrastructure segment drove growth with $373.9M in Q4 revenue (+65.7% YoY) and $1.8B backlog
  • Life Sciences secured 600-system minimum purchase commitment in China; MediBeacon received FDA approval for next-gen system
  • Spectrum segment declined with Q4 revenue of $5.7M (-16.2% YoY) and Adjusted EBITDA down to $1.0M from $2.3M
  • Cash and cash equivalents rose to $112.1M from $48.8M YoY

Financial Impact

Revenue increased by $146.1M YoY in Q4 and $138.9M for the full year, but full-year profitability and Adjusted EBITDA declined despite quarterly improvement. Interest expense rose $14.5M for the year.

revenueepsebitdainterest expensecash

Risk Factors

  • Full-year net loss and Adjusted EBITDA both declined despite strong revenue growth
  • Spectrum segment continues to weaken with advertising softness and network cancellations
  • Rising interest expense ($89.0M in 2025 vs $74.5M in 2024) pressures earnings

Market Snapshot

Exchange
NYSE
Sector
Fabricated Structural Metal Products

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3263408
8 reports for VATE
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for VATE — sortable, filterable
Type Now
Jun 1, 2026
12d ago
8-K
NEUTRAL ★ 6/10
$15.89 $18.98▲ +19.45%▲ +22.20%$16.72 (+5.22%)
Jun 1, 2026
12d ago
Press Release
BULLISH ★ 7/10
$15.89 $18.98▲ +19.45%▲ +22.20%$16.72 (+5.22%)
May 14, 2026
29d ago
8-K
NEUTRAL ★ 5/10
$10.66 $13.10▲ +22.89%▲ +21.93%$16.72 (+56.85%)
Apr 27, 2026
6w ago
Press Release
NEUTRAL ★ 1/10
$12.33 $12.78▲ +3.65%▲ +1.96%$16.72 (+35.60%)
Apr 6, 2026
9w ago
8-K
NEUTRAL ★ 3/10
$7.49 $9.33▲ +24.57%▲ +20.43%$16.72 (+123.23%)
Apr 6, 2026
9w ago
Press Release
NEUTRAL ★ 3/10
$7.49 $9.33▲ +24.57%▲ +20.43%$16.72 (+123.23%)
Mar 26, 2026
11w ago
Press Release
MIXED ★ 6/10
$4.59 $7.49▲ +63.18%▲ +59.32%$16.72 (+264.27%)
Mar 16, 2026
12w ago
Press Release
NEUTRAL ★ 3/10
$4.30 $4.21▼ −2.09%▲ +0.56%$16.72 (+288.84%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (47h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access